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X‑Ray Crystallography and its Role 
in Understanding the Physicochemical Properties 
of Pharmaceutical Cocrystals
1 Introduction
Any matter on the earth is made up of atoms con-
nected by interatomic bonds. The precise nature 
of the interatomic bonds determines the proper-
ties of the matter. Curiosity over understanding 
the properties of a material led to investigate how 
in different ways the atoms are arranged to form a 
certain molecule and intermolecular bonds that 
connect the molecules to form the solid. In this 
regard, X-ray crystallography is undoubtedly the 
most comprehensive technique available to deter-
mine the atomic positions, intermolecular inter-
actions, and the overall structure of any molecule 
at atomic resolution.1 From the first use for deter-
mination of crystal structure of NaCl, X-ray dif-
fraction has received paramount importance in 
many fields of science for understanding the 
X-ray crystallography: An 
analytical technique used for 
determining the atomic and 
molecular structure of a crys-
tal, in which the crystalline at-
oms cause a beam of incident 
X-rays to diffract into many 
specific directions.
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Abstract | Properties of a matter are intrinsically dependent on the inter‑
nal arrangement of molecules in the solid state. Therefore, knowledge 
of three‑dimensional structure of the matter is a prerequisite for struc‑
ture–property correlations and design of functional materials. Over the 
past century, X‑ray crystallography has evolved as a method of choice 
for accurate determination of molecular structure at atomic resolution. 
The structural information obtained from crystallographic analysis paved 
the way for rapid development in electronic devices, mineralogy, geo‑
sciences, materials science, pharmaceuticals, etc. Knowledge of the 
structural information of active pharmaceutical ingredients (APIs) is 
a prerequisite for rational drug design and synthesis of new chemical 
entities for development as new medicines. Over the past two decades, 
X‑ray crystallography has played a key role in the design of pharmaceu‑
tical cocrystals—crystalline solids containing an API and one or more of 
pharmaceutically acceptable coformers. These materials have proved 
promising for fine‑tuning several important properties of APIs. This short 
review highlights the history of crystallography, early breakthroughs, and 
the role of crystallography in understanding the physicochemical proper‑
ties of pharmaceutical cocrystals.
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structure–property correlations.2 For example, 
the fact that the hardness of diamond and the 
brittleness of graphite are due to the different 
ways that the carbon atoms are arranged in the 
crystal lattice would not have been revealed unless 
their crystal structures were determined by X-ray 
diffraction.
Over the past 100 years, diffraction-based 
crystallography has become a mainstream and 
powerful experimental tool to determine the 
three-dimensional structure of small and mac-
romolecules.3 Many pioneering works have led 
to the crystallography to a state where it stands 
today as a mature discipline of far-reaching 
impact on material characterization and analy-
sis. The emergence of X-ray crystallography 
ensued greater understanding of the properties 
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of materials and functioning of biological mol-
ecules. The structural insights obtained from 
crystallographic analysis led to unprecedented 
developments in electronic devices, mineralogy, 
geosciences, materials science, and pharmaceuti-
cals. Knowledge of accurate structural informa-
tion of active pharmaceutical ingredients (APIs) 
is a prerequisite for rational drug design and syn-
thesis of new chemical entities for the develop-
ment of new medicines.4 With a focus on the role 
of crystallography in modern drug development, 
this review is an attempt to highlight the brief 
history of crystallography, early breakthroughs, 
and the role of crystallography in understanding 
the physicochemical properties of pharmaceutical 
cocrystals.
1.1  History of X‑ray Crystallography
The discovery and development of X-ray crystal-
lography as a tool for precise analysis of solid-
state matter is the result of many pioneering 
works. X-rays were discovered by W. C. Röentgen 
in 1895.5 The ability of X-rays to be diffracted 
by single crystals was demonstrated by M. von 
Laue in 1912, which earned him the Nobel Prize 
for physics in 1914.6 In the subsequent year, W.L. 
Bragg formulated the diffraction law famously 
known as Bragg’s law, who demonstrated the 
use of diffraction pattern to determine the crys-
tal structure of NaCl7. His father, W. H. Bragg, 
had pioneered the design of instrumentation to 
Bragg’s law : It refers to the 
simple equation: nλ = 2d 
sinθ which explains why 
the cleavage faces of crystals 
appear to reflect X-ray beams 
at certain angles of incidence 
(θ, λ), where d is the distance 
between atomic layers in a 
crystal and λ is the wavelength 
of the incident X-ray beam. 
When X-rays strike a crystal, 
they will be diffracted only 
when this equation is satisfied.
X-rays: Electromagnetic ra-
diation of wavelength 0.1–100 
Å, produced by bombarding 
a target (generally a metal 
such as Cu or Mo) with fast 
electrons.
observe diffraction patterns. Bragg’s law (named 
only after the son, W. L. Bragg) was used to ana-
lyze the diffraction pattern and their joint and 
independent studies earned the Braggs (father 
and son) the Nobel Prize in Physics in 1915. The 
importance and applications of X-ray diffraction 
in several scientific fields have led to the award of 
29 Nobel Prizes so far. The successful inception 
of crystallography into many scientific fields has 
been recognized by the United Nations, which 
declared 2014 as the International Year of Crystal-
lography.8 It is, therefore, important to mention 
a few ground-breaking discoveries that furthered 
the significance of crystallography.
After the first crystal structure of NaCl was 
determined by X-ray diffraction, it was the dia-
mond structure that established the role of crys-
tallography in understanding material properties. 
The hardness of diamond was established as a 
repetitive tetrahedral arrangement of carbon 
atoms in the crystal lattice (Fig. 1).9, 10 Subse-
quent structural determinations included the 
structures of hexamethylenetetramine, quartz, 
and hexamethylbenzene. It was around late 1920s, 
structural studies on water by W. H. Barnes were 
instrumental in providing unambiguous insights 
into hydrogen bonding in water crystals.11 Since 
then, X-ray diffraction has been a reliable tech-
nique to evaluate the three-dimensional struc-
ture of many other materials including elements, 
binary compounds, and even proteins.
Figure 1: Diamond (left) and graphite (right), two allotropes of carbon, display distinct physical proper‑
ties, which are rationalized on the basis of crystal structure analysis. Reproduced with permission from 
reference 10. Copyright © 2006 The Royal Society of Chemistry.
APIs: According to US Food 
and Drug Administration 
(US-FDA), an API is any 
substance or mixture of sub-
stances intended to be used 
in the manufacture of a drug 
product and that, when used 
in the production of a drug, 
becomes an active ingredient 
in the drug product. Such 
substances are intended to 
furnish pharmacological 
activity or other direct effect 
in the diagnosis, cure, mitiga-
tion, treatment, or prevention 
of disease or to affect the 
structure and function of 
the body.
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The first X-ray diffraction pictures from a small 
hydrated protein, pepsin, were collected by J. D. 
Bernal et al. in 1934.12 About 25 years later, crys-
tal structures of myoglobin and hemoglobin were 
determined by J. Kendrew et al. in 195813 and M. 
Perutz et al. in 1960,14 respectively, which earned 
them the Nobel Prize in Chemistry in 1962. D.C. 
Hodgkin solved the structures of a number of bio-
logical molecules, including cholesterol (1937), 
penicillin (1949)15, vitamin B12 (1954)16, and 
insulin (1969).8 Her seminal works were recog-
nized with a Nobel Prize in Chemistry in 1964.
Chirality is fundamental in biology and drug 
molecules and has tremendous implications in 
drug–receptor interactions. The building blocks of 
proteins, the naturally occurring amino acids, are 
chiral. Milton and coworkers showed that invert-
ing the chirality of an enzyme can lead to a com-
plete inversion in its enantioselectivity.17 Thus, 
absolute configuration is critical for proper func-
tioning of biological systems. Since these break-
throughs, the crystal structure of proteins, nucleic 
acids, and other biological molecules has been 
determined using X-ray crystallography. One of 
the biggest milestones of the 20th century was the 
discovery of the structure of DNA by J. D. Watson 
and F. H. C. Crick which was based on the diffrac-
tion experiments carried out by R. Franklin.18 
Watson and Crick were awarded the Nobel Prize 
in Physiology in 1962, together with M. Wilkins, 
who had worked with Franklin. The discovery of 
the ‘double helix’ paved the way to macromolecule 
and protein crystallography, essential tools of the 
biological and medical sciences today.
Drug design strongly relies on the use of X-ray 
crystallography. A pharmaceutical company look-
ing for a new drug to combat a specific bacterium 
or virus first needs to find a small molecule capa-
ble of blocking the active proteins (enzymes) that 
are involved in attacking the human cell. Know-
ing the precise shape of the protein allows scien-
tists to design drug compounds that can clamp 
onto the ‘active’ site on the protein and thereby 
disable their harmful activity. With the advent of 
powerful X-ray sources (e.g., synchrotrons), new 
detectors, new experimental protocols, and the 
development of modern software, the number of 
accurately determined crystal structures of small 
and macromolecules has exponentially increased. 
Currently, the Cambridge Structural Database 
(CSD),19 which is the storehouse of small mol-
ecule crystal structures, contains more than 
750,000 structures, and the Protein Data Bank20 
over 105,000 structures of biomacromolecules, 
almost 90% of which were determined by means 
of X-ray diffraction.
Absolute configuration: 
Spatial arrangement of the 
atoms of a chiral molecular 
entity (or group) and its ste-
reochemical description, e.g., 
R or S, referring to Rectus, or 
Sinister, respectively.
Chirality: It is a geometric 
property of some molecules 
and ions. A chiral molecule/
ion is non-superimposable 
on its mirror image (Greek: 
cheir = hand). The presence 
of an asymmetric carbon cen-
tre is one of several structural 
features that induce chiral-
ity in organic and inorganic 
molecules.
1.2  Modern developments: structure 
from powder diffraction
Many crystalline solids exist as microcrystal-
line powders and making single crystals suitable 
for structure determination using single-crystal 
X-ray diffraction technique is a daunting task. 
In these instances, X-ray powder diffraction pro-
vides an alternative tool for characterization of 
the crystalline powder materials.21 Over the past 
century, X-ray powder diffraction has evolved as 
one of the most potential characterization tools 
for qualitative and quantitative analysis of pow-
der materials. The technique is non-destructive 
and has been applied to analyze phase purity of 
a wide range of materials from various disciplines 
such as geology, polymeric, environmental, foren-
sic, and pharmaceutical sciences (Fig. 2).22 Semi-
nal works of P. Debye and P. Scherrer on LiF in 
191623 and A. W. Hull on iron and various other 
materials in 191724 mark the beginning of using 
X-ray powder diffraction for material characteri-
zation. For over 50 years, it was primarily used for 
phase identification in mineralogy, metallurgy, 
and solid-state chemistry, and its extension to 
more complex problems, such as structure refine-
ment and structure determination, was limited 
to only simple high symmetry systems. The pio-
neering contributions of H. Rietveld heralded a 
paradigm shift by extending the reach of powder 
methods from simple high symmetry structures 
to complex low symmetry ones. There were a 
number of successful attempts to solve new struc-
tures from powder data by 1970s; however, these 
attempts were primarily based on trial-and-error 
methods. Since high-resolution powder diffrac-
tometers, such as synchrotron X-ray and pulsed 
neutron sources, became available, the field of 
structure determination has transformed from 
an art to science. The first challenge in structure 
determination is to index the diffraction pattern, 
but this was conveniently achieved with high-
resolution data. It was then possible to decom-
pose the powder pattern into an approximate 
set of resolved, integrated intensities, so that the 
conventional structure-solving tools of the time 
could be applied. This met with a striking suc-
cess in the mid-1980s. The unknown structure 
of iron (III) arsenate  (FeAsO4) was solved from 
high-resolution neutron data using direct meth-
ods, namely, the Patterson methods.25 So-called 
ab initio determination of structures from pow-
der data has become routine in recent years.
Structure determination from powder X-ray 
diffraction data has potential applications in 
many important fields where obtaining single 
crystals for crystal structure determination is a 
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challenging task. For example, the intermedi-
ates and products of solid-state reactions could 
be analyzed by powder diffraction for structural 
characterization without the need for crystal-
lization. Multi-component crystals of the type 
of pharmaceutical cocrystals are often prepared 
by solid-state techniques and many cocrystals 
can be prepared only by grinding techniques. 
The microcrystalline powders thus obtained are 
generally not suitable for structural characteri-
zation by single-crystal X-ray diffraction. There-
fore, powder X-ray diffraction is an alternative to 
investigate the structural features of cocrystals. 
For example, K. D. M. Harris and coworkers have 
demonstrated the use of powder X-ray diffraction 
to determine the crystal structure of a cocrystal 
involving racemic bis--naphthol, benzoquinone, 
and anthracene.26 Powder X-ray diffraction has 
also found numerous applications in pharmaceu-
ticals.27 Active pharmaceuticals often go through 
a wide range of processes at preformulation and 
formulation stages of drug development. Hence, 
powder X-ray diffraction plays a key role in the 
evaluation of stability and possible phase con-
versions during manufacturing and formulation 
development. Many a times, solids obtained from 
these processes are not subjected to further crys-
tallization and powder diffraction provides the 
only possible route for determining the crystal 
structure. Crystal structures of many pharmaceu-
tical substances have been determined from pow-
der diffraction data—to name a few, polymorphs 
of fanaserine, talmisartan, fluticasone propionate, 
and tetracaine hydrochloride.
Figure 2: Analytical applications of powder X‑ray diffraction in various fields. Reproduced with permis‑
sion from reference 22. Copyright © 2014, Reviews on Advanced Materials Science.
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1.3  Different Solid Forms and Their role 
in Drug Development
Pharmaceuticals typically consist of one or more 
of APIs which are often formulated into a suitable 
final form comprising inactive ingredients. In the 
context of intrinsic value, APIs are the most valu-
able materials. A majority of drug products in the 
market are developed in the form of solids due to 
ease of making and stability advantages. Amongst 
the various critical issues in drug development, 
tackling poor physicochemical properties, such 
as solubility, stability dissolution rate, hygrosco-
picity, and permeability, remain of paramount 
importance. If a particular solid form has any 
issue(s) with physicochemical properties, drug 
developers often look for alternative solid forms, 
such as amorphous forms, polymorphs, salts, 
solvates/hydrates, and cocrystals.28
Crystalline solids have regular arrangement of 
molecules with repeating units in three dimen-
sions, whereas amorphous solids lack long-range 
order (Fig. 3). Amorphous solids display desirable 
pharmaceutical properties, such as faster dissolu-
tion rate and bioavailability than its crystalline 
form, but they are not as much frequently mar-
keted as crystalline solids owing to their poor 
physical stability and tendency for crystalliza-
tion.29 Hence, a major fraction of marketed phar-
maceuticals consists of APIs in crystalline form. 
These solids can show polymorphism, which is 
defined as the ability of a substance to exist in two 
or more crystalline phases that have different 
arrangements of molecules in crystal lattice. 
Bioavailability: It refers to 
the extent and rate at which 
the active moiety (drug or 
metabolite) enters systemic 
circulation, thereby accessing 
the site of action. Bioavail-
ability of a drug is largely 
determined by the properties 
of the dosage form, which 
depend partly on its design 
and manufacture. Differ-
ences in bioavailability among 
formulations of a given drug 
can have clinical significance; 
thus, knowing whether drug 
formulations are equivalent is 
essential.
Developing a polymorphic form is a promising 
route as it is the only alternative crystalline form 
in the pure form of drug substance. However, 
polymorphic variants only show a marginal solu-
bility improvement and stability is a major con-
cern as the metastable (unstable) polymorphs 
tend to convert to stable form impacting shelf-life 
and drug performance. Hydrates and solvates are 
crystalline solids that contain water and solvents, 
respectively, in the crystal lattice. Though some of 
the existing drug products are developed using 
hydrates or solvates, they are not often regarded 
as preferred solids owing to their low thermal sta-
bility, variable stoichiometry, and limited advan-
tages with physicochemical properties. A 
pharmaceutical salt is formed when an acidic or 
basic drug reacts with basic/acidic salt former. 
The presence of ions in the crystal lattice strongly 
influences the physicochemical properties of the 
API, and the salt formation is the most preferred 
route in the development of APIs as drug prod-
ucts. However, a major setback with salt forma-
tion is that the technique is only applicable to the 
APIs, which are ionizable under normal pH con-
ditions. Solid solutions and eutectic composi-
tions, which are crystalline variable stoichiometry 
multi-components and conglomerates of solid 
solutions, respectively, are relatively less studied 
in pharmaceuticals but have also been explored 
for development of drug products. Over the past 
two decades, cocrystals offered a promising alter-
native route to gain control over physicochemical 
properties of APIs by judicious selection of 
Figure 3: Most common solid forms of pharmaceuticals.
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coformers.30 The advantages with cocrystals over 
other traditional solid forms are discussed in the 
following sections.
2  Cocrystals in Pharmaceutical Design
2.1  Modern Drug Development: Need 
for Better Solid Forms
From finding a drug candidate to bringing a drug 
product to the market, a staggering amount of 
time is spent in its development. It has been esti-
mated that an average of 12 years is required for 
total drug development and it costs about US 
$1.5 billion.31 In the process, thousands of com-
pounds are computationally screened and tested 
for their biological activity, and of the 5000–
10,000 compounds that show promise, five will 
go to human trials, and only one will finally 
become an approved drug. Despite these hard-
ships, if the API identified as suitable candidate 
does not offer promising physicochemical prop-
erties, such as solubility, stability, and dissolution 
rate, it significantly impacts drug development 
from an economic perspective. It is also to be 
highlighted that despite enormous computational 
and experimental advances, the number of new 
chemical entities that are used as drug substances 
has significantly declined. Therefore, modern 
drug development is not only focused on the dis-
covery of new chemical entities, but also on 
exploring ways in which the existing drug sub-
stances can be used effectively. Such a repurpos-
ing of existing drug substances mainly refers to 
studying the drugs that are already approved to 
treat one disease or condition to see if they are 
safe and effective for treating other diseases.32 
Alternatively, it could also mean improvement of 
physicochemical properties of active ingredients 
so as to develop better drugs with improved drug 
performance. This is often carried out by physical 
transformation of an API by making solid disper-
sions, micronization, and amorphous solid forms 
embedded within a polymer matrix.33 An alterna-
tive approach that has tremendous implication in 
drug development is to make novel solid forms of 
APIs, such as salts, polymorphs, solvates, hydrates, 
and cocrystals. Irrespective of the solid form cho-
sen for development of a drug, APIs are seldom 
administered alone; rather they are given as part 
of formulation in combination with other inac-
tive substances which aid the development of a 
suitable formulation for an appropriate mode of 
administration. While the biological action of the 
drug product depends on the activity of the API, 
its physicochemical properties determine how 
well the API is absorbed in the body to perform 
Micronization: It is the pro-
cess of reducing the average 
diameter of a solid material’s 
particles. The traditional 
techniques for micronization 
focus on mechanical means, 
such as milling and grinding. 
Micronization is one of the 
most common techniques of 
particle size reduction in drug 
development.
Solid dispersions: It refers 
to a group of solid products 
consisting of at least two dif-
ferent components, generally 
a hydrophilic matrix and a 
hydrophobic drug. The matrix 
can be either crystalline or 
amorphous. Solid dispersion 
technique is one of the most 
promising techniques for en-
hancement of drug solubility 
and dissolution rate conse-
quently the bioavailability of 
poorly soluble drugs.
its action. Therefore, it is important to under-
stand the physical description of the API prior to 
development of a dosage form. As discussed in 
the previous section, a given API can form a wide 
variety of solid forms and each has its own phys-
icochemical properties, which could impact the 
formulation development. Thus, the complex 
nature of formulation development and manu-
facturing operations demands a closer look at 
how the properties of a given drug vary from one 
solid form to the other.
Pharmaceutical salts are by far the most com-
monly used solid forms for development of drug 
formulations. It is estimated that approximately 
50% of drugs contain the active ingredient in salt 
form.34 Salt formation has a number of poten-
tial advantages. For example, salts are known 
to improve solubility, dissolution rate, melting 
point, photostability, processability, better taste, 
etc. A large number of monographs and books 
highlight the importance of salt formation in 
drug development. Despite widespread applica-
tion of salt formation in drug development, the 
technique is limited to only APIs that are ioniz-
able under normal pH conditions. Many drug 
products and drug substances in the developmen-
tal stages contain APIs that fall into this category. 
Therefore, alternative technique such as pharma-
ceutical cocrystallization is important for prob-
ing solid-form diversity of APIs. Cocrystallization 
scores additional advantages over salt formation 
as it can be applied even to non-ionizable APIs. 
Pharmaceutical cocrystals are made with cofor-
mers that are chosen from the list of Generally 
Recognized As Safe (GRAS) chemicals. GRAS 
chemicals are food additives considered safe for 
human consumption35 and their list constitutes a 
wide range of chemicals like aldehydes, alcohols, 
carboxylic acids, amides, and sweeteners. There-
fore, the diversity of GRAS chemicals in terms of 
their structure and physicochemical properties 
provides an additional means of selecting a suit-
able coformer for a target change in the API. Over 
the past decade, alongside other well-known solid 
forms, such as salts, polymorphs, and hydrates/
solvates, cocrystals have shown immense promise 
in easing formulation development by addressing 
the physicochemical problems of APIs.
2.2  Impact of cocrystals on drug 
development
Physicochemical properties of an API differ from 
one solid form to the other which is often a con-
sequence of the way the API molecules are 
arranged in the crystal lattice of that solid form. 
Encapsulation: It is a process 
in which particles of a 
substance are surrounded by 
a coating to give capsules of 
many useful properties. In 
pharmaceuticals, encapsula-
tion of drug molecules into 
microspheres or nanoparticles 
enables controlled drug re-
lease, taste masking, improv-
ing stability, and protection 
of protein and peptide from 
degradation.
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its action. Therefore, it is important to under-
stand the physical description of the API prior to 
development of a dosage form. As discussed in 
the previous section, a given API can form a wide 
variety of solid forms and each has its own phys-
icochemical properties, which could impact the 
formulation development. Thus, the complex 
nature of formulation development and manu-
facturing operations demands a closer look at 
how the properties of a given drug vary from one 
solid form to the other.
Pharmaceutical salts are by far the most com-
monly used solid forms for development of drug 
formulations. It is estimated that approximately 
50% of drugs contain the active ingredient in salt 
form.34 Salt formation has a number of poten-
tial advantages. For example, salts are known 
to improve solubility, dissolution rate, melting 
point, photostability, processability, better taste, 
etc. A large number of monographs and books 
highlight the importance of salt formation in 
drug development. Despite widespread applica-
tion of salt formation in drug development, the 
technique is limited to only APIs that are ioniz-
able under normal pH conditions. Many drug 
products and drug substances in the developmen-
tal stages contain APIs that fall into this category. 
Therefore, alternative technique such as pharma-
ceutical cocrystallization is important for prob-
ing solid-form diversity of APIs. Cocrystallization 
scores additional advantages over salt formation 
as it can be applied even to non-ionizable APIs. 
Pharmaceutical cocrystals are made with cofor-
mers that are chosen from the list of Generally 
Recognized As Safe (GRAS) chemicals. GRAS 
chemicals are food additives considered safe for 
human consumption35 and their list constitutes a 
wide range of chemicals like aldehydes, alcohols, 
carboxylic acids, amides, and sweeteners. There-
fore, the diversity of GRAS chemicals in terms of 
their structure and physicochemical properties 
provides an additional means of selecting a suit-
able coformer for a target change in the API. Over 
the past decade, alongside other well-known solid 
forms, such as salts, polymorphs, and hydrates/
solvates, cocrystals have shown immense promise 
in easing formulation development by addressing 
the physicochemical problems of APIs.
2.2  Impact of cocrystals on drug 
development
Physicochemical properties of an API differ from 
one solid form to the other which is often a con-
sequence of the way the API molecules are 
arranged in the crystal lattice of that solid form. 
Encapsulation: It is a process 
in which particles of a 
substance are surrounded by 
a coating to give capsules of 
many useful properties. In 
pharmaceuticals, encapsula-
tion of drug molecules into 
microspheres or nanoparticles 
enables controlled drug re-
lease, taste masking, improv-
ing stability, and protection 
of protein and peptide from 
degradation.
Hence, selection of a solid form has profound 
implications in clinical, legal, and regulatory per-
spective. It has been estimated that approximately 
80% of the drugs currently under development 
belong to Class II or IV of the biopharmaceutical 
classification system (BCS). Poor solubility is the 
characteristic nature of the drugs that fall into 
these classes. Drug formulators often rely on 
techniques such as micronization, solid disper-
sion, encapsulation, salt formation, amorphous 
forms, etc., for addressing solubility issues. How-
ever, these techniques have inherent drawbacks in 
manufacturing and additional risk of stability of 
resulting formulations. Cocrystals (Table 1) are 
attractive solid forms for addressing solubility 
issues of BCS Class II and IV drugs. In addition, 
many solid-state problems such as physical stabil-
ity, hygroscopicity, melting point, and dissolution 
rate could be modified by selecting an appropri-
ate coformer.28, 30 From an intellectual property 
perspective, the emergence of cocrystals as novel 
solid forms provided new avenues for extending 
patent life of parent drugs. Cocrystals that show 
improved physicochemical properties satisfy the 
three criteria required for issuing a patent: (1) 
novelty, every cocrystal is novel as it is not possi-
ble to predict whether a combination of an API 
and coformer forms a cocrystal, (2) 
non-obviousness, the physicochemical and phar-
macokinetic properties of APIs are difficult to 
predict unless detailed experiments were con-
ducted, (3) utility, the main motivation in the 
development of cocrystals is due to their ability to 
improve the performance of the parent drug. A. 
V. Trask puts forth the patentability aspects of 
pharmaceutical cocrystals.36 With the interest in 
pharmaceutical cocrystals growing, there is a 
plethora of patent applications on cocrystals. The 
potential applications of cocrystals in the devel-
opment of drug formulations has been recog-
nized by several pharmaceutical companies and 
many have even recognized the need for their 
screening as part of solid-form screening for 
identifying an optimal solid form for develop-
ment. The importance of pharmaceutical cocrys-
tals has been recognized recently by the US Food 
and Drug Administration (FDA, 2011)37 and 
European Medicines Agency (EMA, 2014),38 
which released draft guidelines on the subject of 
regulatory classification of pharmaceutical 
cocrystals. While FDA classified pharmaceutical 
cocrystals as drug product intermediates and the 
coformers used to make the cocrystals are defined 
as excipients, EMA defined them as being solid-
state variants of the APIs, aligning them with 
salts, polymorphs, hydrates, or solvates. The views 
Table 1 Milestones in the area of cocrystal research
Year Milestone
1844 Discovery of the first cocrystal by F. Wöhler involving benzoquinone and hydroquinone (termed as quinhy-
drone)
1963 First use of the term “cocrystal” by W.R. Lawton and E.F. Lopez for crystalline complexes involving organic 
amines and bisphenol
1974–
91
Several drug–drug molecular complexes (cocrystals) involving antipyrene and salicylic acid, theophylline and 
phenobarbital, pyrimidine and barbituric acid, and sulfaproxyline and caffeine, etc
1990 “Rules” of hydrogen bonding proposed by M.C. Etter are useful for predicting hydrogen-bond patterns in 
organic crystals (including cocrystals)
1995 Introduction by G.R. Desiraju of the concept of supramolecular synthons in crystal engineering. This has had 
profound impact on the design of cocrystals
2004 Seminal feature article by Ö. Almarsson and M.J. Zaworotko in Chemical Communications: Formal begin-
ning of the subject of pharmaceutical cocrystals
2005 An article by M.J. Zaworotko and coworkers that raised, for the first time, the question: are cocrystals less or 
more prone to polymorphism?
2007 A comprehensive review by A. V. Trask on patentability aspects of pharmaceutical cocrystals
2009 Indo-US Workshop on pharmaceutical cocrystals and polymorphs
2011 US-FDA’s guidance on regulatory classification of cocrystals
2014 EMA’s reflection paper on the use of cocrystals in medicinal products
2015 Entresto: first marketed cocrystal post US-FDA’s guidance (2011) on cocrystals that consist of disodium val-
sartan and monosodium sacubitril. The drug was launched by Novartis for the treatment of chronic heart 
failure
2016 US-FDA’s revised guidance on cocrystals, which eases the regulatory burden of pharmaceutical cocrystals
234
Srinivasulu Aitipamula and Venu R. Vangala 
1 3 J. Indian Inst. Sci.| VOL 97:2 | 227–243 June 2017 | journal.iisc.ernet.in
of the regulatory bodies, in particular FDA, are 
contrary to what the current understanding of 
the concept of pharmaceutical cocrystals is that 
the second component in a cocrystal is a pharma-
ceutically acceptable coformer. In addition, by 
classifying them as drug product intermediates, 
cocrystals have to comply with additional current 
good-manufacturing practice requirements 
(cGMPs). Therefore, to address the industry con-
cerns and also to ease the regulatory burden, the 
FDA has most recently reclassified them (August 
2016) as a special class of solvates in which the 
second component is non-volatile.39 Further-
more, the FDA made sure that their regulatory 
classification is similar to that of a polymorph of 
the API, meaning that cocrystals do not require 
regulatory approvals as is required by a new API 
or a drug intermediate.
2.3  Molecular Insights into Cocrystal 
Formation
Cocrystals are defined as multi-component crys-
tals composed of two or more solid components 
in stoichiometric ratio.40 Non-covalent interac-
tions of the type hydrogen bonds are often 
responsible for the association of solid compo-
nents in a cocrystal. Therefore, knowledge of 
intermolecular interactions between the molecu-
lar components is a prerequisite for a successful 
cocrystal design. In this regard, G.R. Desiraju’s 
supramolecular synthon concept41 and M.C. 
Etter’s hydrogen-bonding “rules” 42 provide valu-
able insights into the association of two or more 
molecules in the crystal lattice. Recurring inter-
molecular interactions in a crystal structure are 
termed supramolecular synthons and are further 
classified into two basic types. One that involves 
the same functional groups is called supramolec-
ular homosynthon and the one that involves dif-
ferent but complementary functional groups is 
called supramolecular heterosynthon. As the 
cocrystals are formed due to intermolecular 
interactions between two or more different mole-
cules, the supramolecular heterosynthons of the 
type that involve functional groups of different 
molecules play an important role in the design of 
cocrystals.
Crystal engineering was defined by G. R. 
Desiraju as “the understanding of intermolecu-
lar interactions in the context of crystal pack-
ing and in the utilization of such understanding 
in the design of new solids with desired physical 
and chemical properties” reinforces the molecular 
recognition between molecules through a knowl-
edge of intermolecular interactions.43 Therefore, 
Supramolecular synthons: 
Structural units within super-
molecules (crystals) that can 
be formed and/or assembled 
by known or conceivable 
synthetic operations involving 
intermolecular interactions. 
Design of cocrystals generally 
relies on identification of ro-
bust supramolecular synthons 
between the constituents of 
the cocrystal.
Hydrogen-bonding rules: 
(1) All good proton donors 
and acceptors are used in 
hydrogen bonding. (2) Six-
membered-ring intramolecu-
lar hydrogen bonds form in 
preference to intermolecular 
hydrogen bonds. (3) The best 
proton donors and acceptors 
remaining after intramolecu-
lar hydrogen-bond formation 
will form intermolecular 
hydrogen bonds to one 
another. These rules correlate 
functional groups in neutral 
organic molecules with 
hydrogen-bond patterns in 
crystals and useful for selec-
tion of suitable coformers for 
the design of cocrystals.
Hydrogen bonds: It is an 
attractive interaction between 
a hydrogen atom from a 
molecule or a molecular frag-
ment X–H in which X is more 
electronegative than H, and 
an atom or a group of atoms 
in the same or a different 
molecule, in which there is 
evidence of bond formation.
crystal engineering strategies serve as guiding 
principles for the design of cocrystals. The knowl-
edge obtained from the analysis of the crystal 
structures deposited in the Cambridge Structural 
Database (CSD) is used in the selection of cofor-
mers for cocrystal formation. A successful cocrys-
tal design demands supramolecular synthons 
that are observed most frequently between the 
functional groups present on the components 
of cocrystals. Hence, the design of cocrystals for 
a given molecule starts with analyzing the func-
tional groups available on that molecule and 
finding complementary functional groups which 
would likely form predictable supramolecu-
lar synthons. Thus, the coformer selection in a 
cocrystal design strategy reinforces a greater role 
of the knowledge of intermolecular interactions 
which is often drawn from X-ray crystal structure 
analysis.
3  Physicochemical Properties 
of Pharmaceutical Cocrystals
Cocrystallization is the result of molecu-
lar recognition between two or more differ-
ent molecules through energetically favorable 
intermolecular interactions. The strength of 
intermolecular interactions and the way that 
the constituents of the cocrystal arranged in the 
crystal lattice determine its physicochemical 
properties. Hence, it is important that a detailed 
structural analysis is a prerequisite for under-
standing the physicochemical properties, which 
not only results in structure–property correla-
tion, but also aids in subsequent design of cocrys-
tals for fine-tuning the API properties. Over the 
past century, single-crystal X-ray diffraction has 
proven to be an important tool for unambigu-
ous determination of crystal structures, and thus, 
assisted in ground-breaking analysis of material 
properties. With respect to cocrystals, structural 
characterization (a) establishes the reliability of 
cocrystal design strategy, (b) reveals hydrogen-
bond preferences of the functional groups, and 
(c) provides insights into structure–property 
correlation.
The existing vast literature on cocrystals pro-
vides a breadth of knowledge on their diverse 
applications. These primarily deal with improve-
ment in solubility, dissolution rate, stability, color, 
melting point, mechanical strength, etc.28, 30 
Recently, cocrystals have also been found to mod-
ify properties such as permeability of drugs,44 
explosive nature of energetic materials,45 non-lin-
ear optical properties of organic crystals.46 This 
section of the review is exclusively focused on 
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some properties of cocrystals for which X-ray dif-
fraction is instrumental in evaluating the struc-
ture–property correlations.
3.1  Reduced Solubility of Sulfacetamide 
for Improved Drug Residence Time
Solubility is an important parameter in determin-
ing the bioavailability of a drug. Pharmaceutical 
cocrystals have proven to be valuable for address-
ing solubility and dissolution rate issues of several 
BCS Class II and IV drug substances, for which 
low solubility is a serious concern in develop-
ment of drug formulations. While a large num-
ber of cocrystals have been reported that showed 
improved solubility of API, attempts to reduce 
the solubility of an API through cocrystalliza-
tion are seldom reported. One such study that has 
demonstrated the application of cocrystallization 
technique in controlling the solubility of an API 
was reported by A. Nangia and coworkers using 
an antibiotic, sulfacetamide (SACT).47 SACT is a 
commonly prescribed topical antibiotic to treat 
conjunctivitis and other ocular ailments; how-
ever, its therapeutic efficacy is severely limited by 
physiological constraints such as tear flow and 
reflex blinking, and results in considerable drug 
loss. Such a limitation necessitates frequent dos-
ing, which is often inconvenient to patients and 
amounts to excess drug loading. The authors have 
hypothesized that if the weaker hydrogen-bond-
ing synthons in the crystal structure of SACT are 
replaced with stronger hydrogen bonds by way of 
cocrystallization, then the resulting stable cocrys-
tal may be useful to lower the solubility of the 
parent drug. Crystal structure of the parent SACT 
features self-assembly of the SACT molecules 
through intermolecular N–H···O hydrogen bonds 
supported by a single auxiliary C–H···O interac-
tion. By employing a crystal engineering strategy, 
the authors have prepared a series of cocrystals 
and analyzed crystal structures and evaluated 
the physicochemical properties. Interestingly, 
the cocrystals showed low solubility and dissolu-
tion rate compared to the parent API. The crystal 
structure of sulfacetamide-caffeine (SACT-CAF) 
cocrystal features the SACT molecules propagat-
ing through stronger heteromeric interactions of 
the type N–H···O and N–H···N hydrogen bonds 
and further stabilized by C–H···O interactions 
(Fig. 4). The heteromeric interactions afford the 
cocrystal better packing efficiency and stronger 
crystal lattice, which showed lower solubility and 
dissolution rate of SACT. It has also been found 
that the cocrystal is stable under slurry and accel-
erated test conditions—a consequence of the 
stronger crystal lattice of the cocrystal. The low 
solubility and good stability of the SACT-CAF 
Figure 4: Crystal packing in the parent SACT (a), SACT‑CAF cocrystal (b), and comparison of the dis‑
solution rate of cocrystals and the API (c). Reproduced with permission from reference 47. Copyright © 
2014, The Royal Society of Chemistry.
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cocrystal could potentially address the poor resi-
dence time and faster elimination issues of SACT 
similar to extended release formulations.
3.2  Improved permeability 
of hydrochlorothiazide 
through cocrystallization
Permeability across barrier tissue, for instance, 
gastrointestinal mucosa, determines absorption 
and distribution of drugs. To improve perme-
ability, lipophilic and non-ionizable drugs are 
preferred, but such drugs can cause poor solubil-
ity and thus result in low oral absorption. Per-
meability along with solubility may provide an 
insightful understanding of bioavailability. The 
amount of drug transported at the membrane is 
a function of the concentration gradient. Hence, 
high-soluble drugs may be absorbed well. The 
diffusion behavior is also dependent on the par-
ticle size. The in vitro diffusion measurements 
are commonly performed using parallel artificial 
membrane permeability assay and Caco-2 cells.
Cocrystallization of APIs for improving 
aqueous solubility has been a well-established 
technique; however, studies on improving drug 
permeability through cocrystallization have been 
reported only recently. G. R. Desiraju and cow-
orkers demonstrated applications of cocrystals 
in improving the permeability of a BCS Class IV, 
diuretic drug, hydrochlorothiazide (HCT).48 Five 
cocrystals with piperazine (PPZ), picolinamide 
(PCM), tetramethylpyrazine (TMPZ), malona-
mide (MAM), or isoniazid (INZ) were prepared 
and their solubility and permeability evaluated 
using a Franz diffusion cell. The solubility and 
permeability product best represents the impact 
of cocrystallization on pharmacokinetic proper-
ties of HCT. It has been found that the cocrystals 
HCT-PPZ and HCT-PCM showed large enhance-
ment in solubility and flux/permeability com-
pared to HCT itself (Fig. 5). Notably, HCT-PPZ 
cocrystal shows the highest solubility and perme-
ability among all the known HCT cocrystals. The 
diffusion behavior of HCT-MAM, HCT-INZ, 
and HCT-TMPZ was marginally higher than 
that of HCT. The observed improvement in sol-
ubility and permeability of the cocrystals is due 
to the disruption of sulfonamide–sulfonamide 
homosynthon in API by the coformer molecules. 
For example, crystal packing of the HCT-PPZ 
cocrystal features a 2D bilayer of HCT molecules 
via N–H···O and C–Cl···O=S interactions, and 
these layers bridged through PPZ molecules via 
N–H···N hydrogen bonds (Fig. 6). The authors 
proposed that the higher concentration of cocrys-
tals in solution leads to amorphous cocrystal 
formation in solution with moderate or weak 
hydrogen bonds, which could generate high con-
centration gradient at the membrane site. Thus, 
the resulting high transient concentrations over-
come lipophilicity and particle size effects and 
provide improved permeation.
3.3  Improved Bioavailability of the 
Muscle Relaxant, Metaxalone
Metaxalone (MTX) is a muscle relaxant used to 
relieve discomfort associated with acute and pain-
ful musculoskeletal conditions. Its effects have 
Figure 5: Results of permeability studies on HCT and its cocrystals, a cumulative amounts of cocrystals 
diffused vs time. b Flux/permeability of cocrystals vs time. Reproduced with permission from reference 48. 
Copyright © 2016, The American Chemical Society.
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been reasoned to depression of central nervous 
system.49 MTX is currently available in market as 
 Skelaxin® in tablets of strengths 400 and 800 mg. 
It belongs to Class II drugs of BCS and shows 
poor solubility. It has also been reported that the 
oral bioavailability of MTX is greatly influenced 
by food, which impacts dosing needs of a patient. 
The previous attempts to make a sufficiently bio-
available form of MTX have not been successful. 
MTX exists in two polymorphic forms.50 Crys-
tal structures of the polymorphs feature distinct 
hydrogen bonding—one polymorph showing 
imide group of the oxazolidone ring to form 
imide–imide catemer synthon and the other 
to form imide–imide dimer synthon (Fig. 7). 
Nuformix Limited (UK) has recently pursued 
cocrystallization route to modify bioavailability 
of the MTX. Oxazolidone group of the MTX 
was exploited to form a series of cocrystals with 
dicarboxylic acids such as, succinic acid, fumaric 
acid, maleic acid, adipic acid, and salicylic acid.51 
Shown in Fig. 7, the imide–imide dimer synthon 
persists in all the cocrystals, which are further 
hydrogen bonded with the coformers via strong 
hydrogen bonds. The presence of coformer in 
the crystal lattice resulted in a significant change 
in the bioavailability of the MTX. Pharmacoki-
netic (PK) studies in beagle dogs using cocrystals 
with succinic and fumaric acids revealed higher 
plasma concentration and the area under the 
curve (AUC) for cocrystals than the MTX. The 
promising PK properties make the MTX cocrys-
tals valuable for development of novel MTX for-
mulations and are currently in clinical trials.
Figure 6: Packing of the HCT‑PPZ cocrystal: a 2D HCT layers propagated along the ab‑plane. b Packing 
of HCT bilayers through PPZ bridging. Reproduced with permission from reference 48. Copyright © 2016, 
The American Chemical Society.
Figure 7: Hydrogen bonding in MTX polymorphs and its cocrystals. Notice that the imide–imide dimer 
synthon is retained in all the crystal structures of the cocrystals. Reproduced with permission from refer‑
ence 50. Copyright © 2011, The American Chemical Society.
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3.4  Improved Photostability 
of Nitrofurantoin Through 
Cocrystallization
The exposure of photons on pharmaceutical 
materials can have destructive effects impact-
ing quality and efficacy of drug products. As per 
International Conference on Harmonisation 
(ICH) guidelines, photostability testing is an inte-
gral part of pharmaceutical development process. 
The drug products undergo a variety of complex 
photochemical reactions depending upon the 
chemical and physical structure of the materials, 
such that the labile functionalities, such as con-
jugated double bonds or aromatic residues con-
taining N, S, or O, are prone to photochemical 
degradation.
Applications of cocrystals in modulating 
photochemical reactivity of pharmaceuticals 
have been paid less attention until recently. For 
example, V.R. Vangala and coworkers demon-
strated for the first time that the improvement 
in photostability of an antibiotic drug, nitro-
furantoin (NF), can be achieved via cocrystalliza-
tion.52, 53 Stability studies on NF powder sample 
revealed that upon irradiation at 315–400 nm, 
~28% of the sample underwent degradation 
in a week (Fig. 8). Mechanistically, NF photo-
degradation was attributed to rapid isomeriza-
tion at C=N bonds and subsequent degradation 
to 5-nitro-2-furaldehyde and 1-aminohydan-
toin (Fig. 8a). By following a crystal engineer-
ing strategy, the authors have made a series of 
cocrystals and studied their photostability. As 
shown in Fig. 8b, the cocrystals with coformers, 
4-hydroxybenzamide (4HBAM), 3-aminoben-
zoic acid (3ABA), 4-aminobenzoic acid (4ABA), 
and urea, all degraded to a minor extent (<3%), 
except the cocrystal with urea, which showed only 
some degree of stabilization (~17% degraded). 
Interestingly, under similar experimental con-
ditions, photostability of physical mixtures of 
NF and coformers was similar to NF (26–30% 
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Figure 8: a Chemical degradation of nitrofurantoin. Note NF cleavage at azomethine ring, b UV irradiation 
of pure NF, cocrystals, and NF + coformer physical mixture samples up to a week and the photodegrada‑
tion curves show the enhanced photostability of cocrystals, and c solid‑state packing of NF‑3ABA (1:1) 
and note the acid–imide heterosynthon between NF and 3ABA molecules. Reproduced with permission 
from reference 53. Copyright © 2012, The American Chemical Society.
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degradation), suggesting the potential of cocrys-
tallization as a means to control the photodegra-
dation of NF.
The greater photostability of the cocrystals was 
rationalized on the basis of crystal structures. For 
example, NF and 3ABA form planar hydrogen-
bonded sheets in the crystal structure of NF-3ABA 
cocrystal (Fig. 8c). A closer look into the crystal 
structure revealed some important structural fea-
tures: (1) the acid group of 3ABA forms an acid–
imide heterosynthon (via O–H···O and N–H···O 
interactions) with NF, and (2) the amine group of 
3ABA forms four strong hydrogen bonds with the 
remaining hydrogen-bond acceptors of the NF. 
The formation of multiple strong hydrogen bonds 
between the coformer and NF could potentially 
hinder the photoisomerization of C=N and hence 
offer better photostability for the cocrystal. Simi-
larly, greater photostability of the other cocrystals 
could be reasoned to the presence of supramo-
lecular synthons between NF and coformers and 
stronger crystal lattice that hamper the photoi-
somerization of NF at the C=N bond.
3.5  Mechanical Property–Crystal 
Structure Correlations in Cocrystals 
of Paracetamol
Materials undergo deformation on applying 
stress; this includes elasticity, plasticity, viscoelas-
ticity, brittle fracture, fragmentation, or a com-
bination of these based on the nature of applied 
stress and internal structure of the material. A 
proper understanding of these mechanical prop-
erties and material deformation phenomena is 
important for powder compaction and second-
ary processes such as milling. The previous stud-
ies on single-component systems are aimed at 
correlating compaction properties and plastic-
ity of materials. The presence of slip planes and 
crystallographic planes with weakest interactions 
or adjacent planes with higher d-spacing in the 
crystal structure affords greater plasticity and 
Figure 9: Comparison of compressed tablets and crystal structures of PRA and PRA–oxalic acid cocrys‑
tal. Notice that the perfect layered structure of the cocrystal affords improved tabletability. Reprinted with 
permission from reference 54. Copyright © 2009 by John Wiley and Sons, Inc.
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better tabletability. Studies concerning mechani-
cal properties of cocrystals have been conducted 
only recently. For example, W. Jones and cow-
orkers have found that the cocrystals of par-
acetamol (PRA) showed better tabletability than 
the marketed polymorph.54 Most recently, S. P. 
Velaga et al. have demonstrated the relationship 
between mechanical properties and crystal struc-
ture in PRA (form I) and its cocrystals.55 Ther-
modynamically stable Form I of PRA showed 
poor tabletability due to high elastic deformation 
(Fig. 9). However, cocrystals with oxalic acid and 
4,4′-bipyridine, and a salt with HCl displayed 
superior tabletability compared to PRA. The tab-
letability of the substances is shown in the order 
of: OXA > PRA-HCl ≈ PRA-OXA > BPY > PRA-
BPY. A closer look into the crystal structures of 
the cocrystals and Form I revealed that the crystal 
structure of Form I has no slip plane and con-
sisted primarily of interlocked PRA molecules 
held strongly by hydrogen bonds. The rigid 
hydrogen-bonded network affords poor tableting 
properties that resulted in brittleness to the com-
pressed tablets. On the other hand, the cocrystal 
with oxalic acid features catemeric arrangement 
of oxalic acid and PRA molecules that gener-
ate layers parallel to (200) and (100) planes. The 
perfect layered structure of the cocrystal explains 
the greater plastic deformation and better tablet-
ability. These studies underscore the role of crys-
tal packing and the strength of intermolecular 
bonding in determining tablet formation and its 
mechanical strength.
3.6  Marketability of Cocrystals
Marketability of a solid form depends on sev-
eral factors and its promising physicochemical 
properties are undoubtedly the prime considera-
tion. As detailed in Sects. 3.1–3.5, cocrystals have 
proved successful in modifying physicochemical 
properties of several important APIs. The adopt-
ability of cocrystallization technology to a wide 
range of APIs, including the ones that are non-
ionizable, has tremendous implications in drug 
development. The inherent characteristics of 
cocrystals such as novelty, usefulness, and non-
obviousness provide additional means for pat-
enting cocrystals as novel composition of matter. 
A close inspection of the marketed drugs and 
their composition revealed that some of them 
contain the API in cocrystal form. For example, 
well-known drugs such as caffeine citrate, sodium 
valproate–valproic acid, and escitalopram oxa-
late–oxalic acid, all comply with the cocrystal 
definition and marketed even before the concept 
of pharmaceutical cocrystals came to existence.40 
The recognition by US-FDA and EMA has fur-
thered the cocrystallization research into a main 
stream preformulation technique and validated 
the use of cocrystals for drug development. Most 
recently, US-FDA and EMA approved a cocrys-
tal hydrate that contains disodium valsartan and 
monosodium sacubitril (Fig. 10).56 The cocrystal 
was developed by Novartis with the trade name 
Entresto and is used in the treatment of chronic 
heart failure. Some other promising cocrystals 
that are under late- stage development are: a 
drug–drug cocrystal containing a non-steroidal 
anti-inflammatory drug, celcoxib, and an opiod 
drug, tramadol, which has superior analgesic 
efficacy compared to comparable doses of tram-
adol,57 and a cocrystal of an anti-diabetic drug 
ertugliflozin with 5-oxo-proline.58
4  Conclusions
Since its discovery, X-ray crystallography remains 
at the forefront of structural characterization of 
materials. Recent developments such as evolution 
of synchrotron radiation and structure determi-
nation from X-ray powder diffraction data have 
Figure 10: Molecular components of Entresto: disodium valsartan, monosodium sacubitril, and water 
which has been approved by FDA and EMA recently.
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furthered the applications of X-ray crystallog-
raphy to characterization of a broader range of 
materials. The current ease of structure determi-
nation using X-ray crystallography has resulted in 
a paradigm shift from simple three-dimensional 
structural analysis to correlating material prop-
erties with the crystal structure. A wide range of 
material properties have successfully been ration-
alized on the basis of crystal structure, which not 
only unraveled many scientific mysteries but also 
aided rational design of functional materials. In 
pharmaceuticals, X-ray crystallography played a 
phenomenal role in understanding the properties 
of drug molecules, which has several important 
legal and economic impacts. The emergence of 
pharmaceutical cocrystals as alternatives to long-
known salts, solvates/hydrates, polymorphs, etc., 
has provided additional means of fine-tuning 
physicochemical properties of drug molecules. 
In this regard, structural information-deduced 
from X-ray crystal structure analysis provides 
breadth of information for judicious selection of 
coformers for a target change in drug property. 
Changes in drug properties such as solubility, 
dissolution rate, physical and chemical stability, 
permeability, and hygroscopicity have success-
fully been correlated with the crystal structures 
of API and its cocrystals. It has been rationalized 
that the coformers that result in significant differ-
ence in the crystal structure of API have profound 
impact on drug properties. Therefore, design of 
pharmaceutical cocrystals demands knowledge 
of competition among various possible intermo-
lecular interactions between API and coformers. 
Despite a significant development in the field 
of cocrystal design, there remain further chal-
lenges. For example, (1) the presence of multiple 
hydrogen-bonding sites on the API or the selected 
coformer increases the complexity and hinders 
application of the traditional cocrystal design 
strategies. Greater understanding of hydrogen-
bonding preferences of a particular functional 
group in the presence of other functional groups 
provides valuable insights into successful cocrys-
tal design; (2) while current cocrystal design 
strategies are aimed at identifying coformers 
based on the functional groups present on a given 
API, the design of cocrystals for molecules that 
lack potential hydrogen-bonding sites remains 
to be explored further. Such molecules are often 
prone to close packing via van der Waals interac-
tions and there exists no reliable strategy for pre-
dicting cocrystal formation. A plausible solution 
to address this issue is to use knowledge-based 
methods, which incorporate structural, geometri-
cal, and chemical information pertaining to the 
API and coformers.59 The recent developments 
in cocrystal research suggest reliable pathways to 
identify suitable solid forms for development of 
novel drug formulations. In this regard, crystal 
structures deposited in the CSD serve as valu-
able source of information for the design of func-
tional cocrystals. Over the past century, the role 
of X-ray crystallography as a tool to probe the 
structure and function of materials has greatly 
been acknowledged. Prediction of properties of 
a material based solely on its crystal structure is 
an emerging area of research and efforts in this 
direction further underscore the importance of 
X-ray crystallography.
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